Open-Label Study to Evaluate the Efficacy and Safety of Oral Ibrexafungerp (SCY-078) in Patients With Candidiasis Caused by Candida Auris (CARES)

PHASE3CompletedINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

November 15, 2017

Primary Completion Date

April 14, 2023

Study Completion Date

May 24, 2023

Conditions
Candidiasis, InvasiveCandidemia
Interventions
DRUG

SCY-078

Oral SCY-078

Trial Locations (12)

1692

Johese Clinical Research, Midstream, Pretoria

74800

Aga Khan University Hospital, Karachi

110017

Institute of Critical Care Medicine Max Super Specialty Hospital, Saket

160012

Postgraduate Institute of Medical Education and Research, Department of Anaesthesia and special care, Chandigarh

226003

King George Medical University, Lucknow

560034

St John's Medical College and Hospital, Bangalore

682041

Amrita Institute of Medical Sciences (AIMS), Kanayannur

07302

Scynexis, Inc., Jersey City

0157

Johese Clinical Research, Unitas Hospital Centurion,, South Africa, 0157, Centurion

0002

Emmed Research, Jakarta Hospital, Pretoria

Zuid Afrikaans Hospital, Pretoria

0181

Into Research, Life Groenkloof Hospital, Pretoria

All Listed Sponsors
lead

Scynexis, Inc.

INDUSTRY

NCT03363841 - Open-Label Study to Evaluate the Efficacy and Safety of Oral Ibrexafungerp (SCY-078) in Patients With Candidiasis Caused by Candida Auris (CARES) | Biotech Hunter | Biotech Hunter